Small molecule · Inhibitor of thymidine phosphorylase · developed by Taiho Pharmaceutical Co.
Tipiracil is a thymidine phosphorylase inhibitor that is combined with trifluridine in a fixed-ratio oral formulation. By blocking thymidine phosphorylase, it slows the breakdown of trifluridine, increasing its exposure, and it is studied in metastatic colorectal cancer.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Nov 5, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04854434 | Phase 2 | Metastatic Colorectal Cancer | Terminated | KPTI |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Metastatic Colorectal Cancer
Updated Oct 18, 2026.